Biomax Informatics : Universities use NeuroXM™ to study the connectome in drug-resistant epilepsy
Using Biomax Informatics' NeuroXM knowledge management platform, scientists from the Universities of Nottingham, Newcastle, Qingdao, Shanghai and Munich have studied the change in the connectome in drug-resistant epilepsy patients. They discovered that connectivity between and within brain regions can be a precise predictor for disease progression and epilepsy surgery outcome.
The NeuroXM Brain Science Suite of Biomax was used to develop a knowledge model for high-resolution intra-areal connectivity with more than 50,000 cortical nodes and several million connections, as well as corresponding automated processing pipelines. This connectivity network could then be visualized and accessed via the web portal of NICARA™, the neuroimaging solution offered by Biomax. "Our experience shows us that our software can be easily deployed in hospitals," explained project leader Dr. Markus Butz-Ostendorf of Biomax. "In addition, it can also be combined with other data from genetics or from other imaging approaches such as PET, CT or EEG."
Dr. Marcus Kaiser, Professor of Neuroinformatics at the University of Nottingham, confirms, "The use of NeuroXM and NICARA is central to this research project. With the help of this advanced neuroimaging solution, we can analyze and evaluate the changes in the local network within brain regions and thus assess whether surgery will be successful or not."
The results from this study have now been published in the journal Human Brain Mapping.
End of Press Release
Chen, X., Wang, Y., Kopetzky, S. J., Butz-Ostendorf, M., & Kaiser, M. (2021). Connectivity within regions characterizes epilepsy duration and treatment outcome. Human Brain Mapping,1–15. https://doi.org/10.1002/hbm.25464CHEN ET AL. 15.
About the NeuroXM Brain Science Suite
The NeuroXM Brain Science Suite provides comprehensive information from neuroimaging, molecular biology, neuro-genomic data, public ontologies and data sets integrated in a unified knowledge model. The extendible network of interrelated neuroscience concepts gives users a single interface to collect knowledge, focus on specific questions and get a greater return on investments in expensive neurological data.
About Biomax Informatics
Biomax Informatics offers software solutions for better decision-making and optimal knowledge management in the life sciences industry. Using the company’s software, customers can generate added value through the integration of information from their own and public resources, enabling them to achieve a knowledge-based approach for the development of innovative life sciences products. Biomax’s global customers include clinics, companies, and research institutions successful in the fields of research into active substances, diagnostics, fine chemicals, and food and plant products. The company, which was founded in 1997 and currently has 45 members of staff, is headquartered in Planegg near Munich. Further information can be found at www.biomax.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CELLTRION-HEALTHCARE12.6.2021 17:47:13 CEST | Press release
Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress
JANSSEN12.6.2021 09:03:12 CEST | Press release
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
JANSSEN12.6.2021 09:02:12 CEST | Press release
New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia
GALDERMA11.6.2021 11:55:08 CEST | Press release
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
SLOTS-CAPITAL11.6.2021 11:24:04 CEST | Pressemeddelelse
Slots Capital er nu tilgængelig for flere spillere end nogensinde før
SLOTS-CAPITAL11.6.2021 11:23:04 CEST | Press release
Slots Capital Available to More Players Than Ever Before
SECURE-COMMUNITIES-FORUM11.6.2021 10:17:07 CEST | Press release
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom